Arch Venture Corp

Latest statistics and disclosures from ARCH Venture Management's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are KRTX, EQRX, ERAS, VERV, OMIC, and represent 99.67% of ARCH Venture Management's stock portfolio.
  • Added to shares of these 6 stocks: KRTX (+$369M), EQRX (+$150M), ERAS (+$95M), VERV (+$57M), OMIC (+$24M), ZY.
  • Started 6 new stock positions in ZY, VERV, OMIC, ERAS, KRTX, EQRX.
  • Reduced shares in these 3 stocks: RUBY (-$13M), Chiasma (-$5.1M), SYRS.
  • Sold out of its positions in Chiasma, SYRS.
  • ARCH Venture Management was a net buyer of stock by $677M.
  • ARCH Venture Management has $698M in assets under management (AUM), dropping by 3384.24%.
  • Central Index Key (CIK): 0001274403

Tip: Access up to 7 years of quarterly data

Positions held by Arch Venture Corp consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for ARCH Venture Management

Companies in the ARCH Venture Management portfolio as of the March 2022 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Karuna Therapeutics Ord (KRTX) 52.9 $369M NEW 2.9M 126.79
Eqrx (EQRX) 21.5 $150M NEW 36M 4.13
Erasca (ERAS) 13.6 $95M NEW 11M 8.60
Verve Therapeutics (VERV) 8.2 $57M NEW 2.5M 22.82
Singular Genomics Systems In (OMIC) 3.4 $24M NEW 3.8M 6.31
Rubius Therapeutics (RUBY) 0.3 $1.9M -86% 350k 5.51
Zymergen (ZY) 0.0 $345k NEW 119k 2.89

Past Filings by ARCH Venture Management

SEC 13F filings are viewable for ARCH Venture Management going back to 2018